Moderna, Inc. (MRNA)
| Market Cap | 49.98B |
| Revenue (ttm) | 15.06B |
| Net Income (ttm) | 4.78B |
| Shares Out | 381.21M |
| EPS (ttm) | 11.62 |
| PE Ratio | 11.23 |
| Forward PE | 32.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,695,156 |
| Open | 131.00 |
| Previous Close | 130.51 |
| Day's Range | 130.60 - 134.59 |
| 52-Week Range | 115.03 - 217.25 |
| Beta | 1.69 |
| Analysts | Buy |
| Price Target | 195.64 (+49.26%) |
| Earnings Date | Aug 2, 2023 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus... [Read more]
Financial Performance
In 2022, Moderna's revenue was $19.26 billion, an increase of 4.29% compared to the previous year's $18.47 billion. Earnings were $8.36 billion, a decrease of -31.47%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MRNA stock is "Buy." The 12-month stock price forecast is $195.64, which is an increase of 49.26% from the latest price.
News
Moderna and Merck reveal new data on individualized cancer treatment
Moderna MRNA, +1.55% and Merck & Co. MRK, +1.43% on Monday released new results from a trial evaluating Moderna's mRNA-based investigational individualized neoantigen therapy in combination with Merck...
Moderna cancer vaccine used with Merck Keytruda reduces risk of deadly skin cancer spreading
Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society.
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage...
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS res...
Moderna to Present at Upcoming Conferences in June 2023
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the fol...
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDT Moderna to host investor event via webcast on Monday, June 5 at 6pm CDT CAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 ...
Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its...
Moderna says looking for opportunities in China after registering legal entity
U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.
Moderna shares react to Covid resurgence news in China
Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.
Report of new COVID wave in China pushes shares of vaccine makers higher
Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the...
Here's what Pfizer and Moderna say is next for their Covid vaccines
Pfizer and Moderna are ushering in a new era for their Covid shots that aims to simplify what people need to do to coexist with the virus.
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging ear...
Rates Have Risen. Here Are 5 Stocks With Little Debt
Thanks to Jerome Powell and his crew at the Federal Reserve, interest rates are about five percentage points higher than they were a year ago. For stock pickers, that means that debt once again matter...
Moderna stock closes higher on earnings beat, unexpected profit
Yahoo Finance Live anchors Akiko Fujita and Seana Smith discuss a rise in shares of Moderna as the company's Q1 earnings beat exceeded investor expectations.
COVID-19 ‘is not leaving the planet,' Moderna CEO says
Moderna Therapeutics CEO Stéphane Bancel joins Yahoo Finance Live to discuss first-quarter earnings, COVID-19 vaccine sales, profit growth, and the outlook for the biotechnology company's RSV vaccine.
Moderna stock rises on Q1 earnings, positive vaccine guidance
Yahoo Finance Live's Rachelle Akuffo and Brad Smith discuss the rise in stock for Moderna following first-quarter earnings.
Moderna Stock Pops on Surprise Earnings Beat
An unexpected profit and promising news on a deal with the EU boosted Moderna stock.
Moderna CEO Stéphane Bancel on surprise Q1 profit, post-Covid future
Moderna CEO Stéphane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, what's next for the biotech company in a post-Covid future, and more.
Moderna posts surprise quarterly profit despite waning demand for Covid vaccines
Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product.
Moderna stock up premarket after posting surprise profit and revenue that crushed estimates
Moderna Inc.'s stock MRNA, -0.96% rose 1.8% premarket Thursday, after the biotech blew past estimates for first-quarter earnings, even as profit and revenue fell sharply amid dwindling demand for COVI...
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to...
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase ...
Moderna Reports Earnings. What Comes After Covid Vaccine Will Be the Focus.
As the biotech reports first-quarter earnings, the focus will be on Moderna's pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales...
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S. The Philippines was select...